Titre :

Refracture And Mortality Following Hospitalization For Severe Osteoporotic Fractures: The Fractos Study

Auteur(s) :

Roux, Christian [Auteur]
Service de rhumatologie [CHU Cochin]
Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques [CRESS (U1153 / UMR_A 1125)]
Thomas, Thierry [Auteur]
Service de Rhumatologie [CHU Saint-Etienne]
Biologie Intégrative du Tissu Osseux [LBTO]
Paccou, Julien [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Bizouard, Geoffray [Auteur]
IQVIA
Crochard, Anne [Auteur]
UCB Pharma S.A.[Braine-l'Alleud]
Toth, Emese [Auteur]
UCB Pharma S.A.[Braine-l'Alleud]
Lemaitre, Magali [Auteur]
IQVIA
Maurel, Frédérique [Auteur]
IQVIA
Perrin, Laure [Auteur]
UCB Pharma S.A.[Braine-l'Alleud]
Tubach, Florence [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]

Titre de la revue :

JBMR Plus

Éditeur :

The american society for bone and mineral research

Date de publication :

2021-05-06

ISSN :

2473-4039

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Severe osteoporotic fractures (hip, proximal humerus, pelvic, vertebral and multiple rib fractures) carry an increased risk of mortality. This retrospective cohort study in the French national healthcare database aimed to ...
Lire la suite >Severe osteoporotic fractures (hip, proximal humerus, pelvic, vertebral and multiple rib fractures) carry an increased risk of mortality. This retrospective cohort study in the French national healthcare database aimed to estimate refracture and mortality rates after severe osteoporotic fractures at different sites, and to identify mortality‐related variables. 356,895 patients hospitalised for severe osteoporotic fracture between 2009 and 2014 inclusive were analysed. The cohort was followed for 2‐8 years up to the study end or until the patient died. Data were extracted on subsequent hospitalisations, refracture events, treatments, comorbidities of interest and survival. Time to refracture and survival were described using Kaplan‐Meier analysis by site of fracture and overall. Mortality risk factors were identified using a Cox model. Hip fractures accounted for 60.4% of the sample (N=215,672). In the 12 months following fracture, 58,220 patients (16.7%) received a specific osteoporosis treatment, of whom 21,228 were previously treatment‐naïve. The 12‐month refracture rate was 6.3% [95%CI: 6.2%–6.3%], ranging from 4.0% [3.7%–4.3%] for multiple rib fractures to 7.8% [7.5%–8.1%] for pelvic fractures. 12‐month all‐cause mortality was 12.8% [12.7%–12.9%], ranging from 5.0% [4.7%–5.2%] for vertebral fractures to 16.6% [16.4%–16.7%] for hip fractures. Osteoporosis‐related mortality risk factors included fracture site, previous osteoporotic fracture (hazard ratio: 1.21 [1.18–1.23]), hip refracture (1.74 [1.71–1.77]) and no prior osteoporosis treatment (1.24 [1.22–1.26]). Comorbid cancer (3.15 [3.09–3.21]) and liver disease (2.54 [2.40–2.68]) were also strongly associated with mortality. In conclusion, severe osteoporotic fractures, including certain non‐hip non‐vertebral fractures, carry a high burden in terms of mortality and refracture risk. However, most patients received no anti‐osteoporotic treatment. The findings emphasise the importance of better management of patients with severe fractures, and of developing effective strategies to reduce fracture risk in patients with osteoporosis.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Marrow Adiposity & Bone Lab (MABLab) - ULR 4490

Source :

Harvested from HAL